This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Reglagene, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Teri C Suzuki: Innovator in Cancer Treatment
Introduction
Teri C Suzuki is a prominent inventor based in Tucson, AZ, known for his significant contributions to cancer treatment through innovative compounds and methods. With a focus on developing small molecules, he has made strides in the medical field, particularly in oncology.
Latest Patents
Teri C Suzuki holds 2 patents that showcase his groundbreaking work. His latest patents include "Compositions and methods for making and using small molecules in the treatment of cancer," which details novel compounds and methods for treating various health conditions, including cancer. This patent outlines methods for administering effective amounts of these compounds to subjects diagnosed with cancer. Another significant patent is "Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions." This patent emphasizes the effectiveness of the disclosed compounds in treating subjects with health conditions, particularly brain cancer, and includes methods for drug screening and detection.
Career Highlights
Teri C Suzuki is associated with Reglagene, Inc., where he continues to advance his research and development efforts in cancer therapies. His work is characterized by a commitment to improving treatment options for patients facing serious health challenges.
Collaborations
Teri collaborates with Vijay Gokhale, contributing to the innovative environment at Reglagene, Inc. Their partnership enhances the potential for developing effective cancer treatments.
Conclusion
Teri C Suzuki's contributions to cancer treatment through his innovative patents and collaborative efforts position him as a key figure in the field of oncology. His work continues to inspire advancements in medical research and patient care.